Compare Adaptive Biotechnologies Corp (ADPT) vs IONQ Inc (IONQ) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

IONQ trades at $48.87, down 0.51% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth with $130.02 million in 2025 and a projected $187 million in 2026, but remains unprofitable with a net loss of $510.38 million in 2025. Recent news highlights its leadership in quantum computing technology and expansion into cybersecurity and space applications, though cash burn remains a concern.

The outlook for IONQ is mixed; analyst consensus is split evenly between Buy and Hold with a $73.75 price target suggesting 51% upside. Key opportunities include technological advantages and commercial partnerships, while risks involve high cash burn, intense competition, and the speculative nature of quantum computing commercialization. Investors should weigh growth potential against financial sustainability.